New blood sugar monitor put to the test in type 1 diabetes trial

NCT ID NCT07296276

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study is testing how well a new continuous glucose monitor, called CareSens Air 3, measures blood sugar levels in adults with type 1 diabetes. Researchers will compare the monitor's readings to standard lab measurements. The goal is to see if the device is accurate and precise enough for everyday use.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
CareSens Air 3 continuous glucose monitoring system
What this could lead to
If successful, this could provide a more accurate and reliable way for people with type 1 diabetes to monitor their blood sugar levels.
What could go wrong
This is a small, early pilot study with only 32 participants, so results may not apply to everyone. The device may not be as accurate as hoped.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for TYPE 1 DIABETES MELLITUS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Atlanta Diabetes Associates

    NOT_YET_RECRUITING

    Atlanta, Georgia, 30318, United States

    Contact Phone: •••-•••-••••

  • Diablo Clinical Research

    RECRUITING

    Walnut Creek, California, 94598, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Headlands Research AMCR

    NOT_YET_RECRUITING

    Escondido, California, 92025, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Rainier Clinical Reseach Center

    RECRUITING

    Renton, Washington, 98057, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.